Mattila Jyrki 4
4 · AUXILIUM PHARMACEUTICALS INC · Filed Mar 3, 2009
Insider Transaction Report
Form 4
Mattila Jyrki
Executive Vice President
Transactions
- Award
Nonqualified Stock Option (Right to Buy)
2009-02-27+20,000→ 20,000 totalExercise: $32.72From: 2009-12-27Exp: 2018-02-22→ Common Stock (20,000 underlying)
Footnotes (2)
- [F1]This option was granted to the reporting person on February 22, 2008 and accrued (subject to vesting) upon the satisfaction of certain performance criteria related to the Company's submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for XIAFLEX for the treatment of Dupuytren's contracture. In the event that the Company's request for Priority Review of the BLA is granted by the FDA, the number of shares underlying this option will increase to 30,000.
- [F2]This option vests 33 1/3% on December 27, 2009 (the 10 month anniversary of the date the performance criteria was met) with the balance vesting in two equal installments on each of October 27, 2010 and August 27, 2011.